Blood

Vol. 146, Issue Supplement 1 Issue Supplement 1 2025
8248
Articles

Articles in this Issue

Chemotherapy-free treatment for children and adolescents with newly diagnosed acute promyelocytic leukemia (APL): Results of the prospective ICC-APL-02 study.

Luisa Strocchio, Pietro Merli, Maria Giuseppina Cefalo et al. Nov 03, 2025 pp. 880-880 10.1182/blood-2025-880

Abstract Introduction: Treatment of acute promyelocytic leukemia (APL) has been revolutionized over the past two decades by the introduction...

Healthcare resource utilization in people with hemophilia treated within vs. outside u.S. hemophilia treatment center network clinics: An interim analysis of the CHESS US study

Enrico Ferri Grazzi, Ming Lim, Nicole Crook et al. Nov 03, 2025 pp. 2615-2615 10.1182/blood-2025-2615

Abstract Introduction People with hemophilia (PwH) in the United States (US) may receive comprehensive care through the Hemophilia Treatment...

The JAK1/2 inhibitor baricitinib revealed unique immune biomarkers in multirefractory immune thrombocytopenia patients

Zhuo-Yu An, Peng Zhao, Hai-Xia Fu et al. Nov 03, 2025 pp. 4820-4820 10.1182/blood-2025-4820

Abstract Introduction Multirefractory immune thrombocytopenia (ITP), defined by resistance to both corticosteroids and t...

SAMHD1 dependence of cgas-sting-associated anti-tumor immune responses in classical Hodgkin lymphoma

Ioanna Xagoraris, Eleni Psaroudaki, Dora Trogrlic et al. Nov 03, 2025 pp. 1782-1782 10.1182/blood-2025-1782

Abstract Background: The tumor microenvironment (TME) plays a pivotal role in the pathogenesis of classical Hodgkin lymphoma (cHL) because o...

Clinical and technological validation of locally-installed, privacy-compliant, and hematology-tailored ambient AI platform for clinical report transcription assistance and clinical trial patient management

Mattia Delleani, Gianluca Asti, Alessia Campagna et al. Nov 03, 2025 pp. 6129-6129 10.1182/blood-2025-6129

Abstract Background Effective communication between clinicians and patients is vital in hematology for personalized treatment. However, trad...

Preliminary results from RIVER-81, a phase 2 study of romaciclib (RVU120) + venetoclax in patients with acute myeloid leukemia failing first-line venetoclax + hypomethylating agent (HMA)

Pau Montesinos, Adolfo De La Fuente Burguera, Sara Garcia Avila et al. Nov 03, 2025 pp. 3424-3424 10.1182/blood-2025-3424

Abstract Background: First-line venetoclax (VEN) in combination with hypomethylating agents (HMA) is the standard of car...

Enhanced clot formation and altered platelet subpopulations in mesothelioma characterized by a high-dimensional analytical platform

Deepa Gautam, Emily M. Clarke, Becky Zon et al. Nov 03, 2025 pp. 1319-1319 10.1182/blood-2025-1319

Abstract Background: Mesothelioma is a rare and aggressive lung cancer primarily caused by asbestos exposure. Thrombotic complications are c...

Eltrombopag plus G-CSF for peripheral blood stem cell mobilization: Final analysis of a single arm, Phase 2 trial

Ta-Chuan Yu, Shang-Ju Wu, Wen-Chien Chou et al. Nov 03, 2025 pp. 5965-5965 10.1182/blood-2025-5965

Abstract Introduction Autologous hematopoietic stem cell transplantation (auto-HSCT) is the standard treatment for relapsed/refractory lymph...

Patterns of patient referral for CAR-T cell therapy: Increasing access and changing utilization trends at a german tertiary care hospital from 2018 to 2024

Christian Rausch, Adrian Gottschlich, Giulia Magno et al. Nov 03, 2025 pp. 4418-4418 10.1182/blood-2025-4418

Abstract CAR-T-cell-therapies (CARTs) have transformed the therapeutic landscape of B- and plasma cell malignancies. However, misconceptions...

Tfr2-mediated erythropoiesis expansion controls systemic glucose homeostasis by modulating erythroid metabolic demand

Simona Maria Di Modica, Emanuele Tanzi, Mara Caputo et al. Nov 03, 2025 pp. 523-523 10.1182/blood-2025-523

Abstract Introduction: Erythropoiesis is a highly energy-demanding and tightly regulated process. It involves cell proliferation, massive he...

Pooled analysis of early-Phase trials highlights robust activity of CD3-CD20 T-cell engagers in follicular lymphoma

Suhib Fahmawi, Forat Lutfi, Jood Ahmad et al. Nov 03, 2025 pp. 5387-5387 10.1182/blood-2025-5387

Abstract Background: Follicular lymphoma (FL) is the most common indolent non-Hodgkin lymphoma. It's characterized by slow disease course bu...

Machine learning-based immunoinflammatory phenotypes predict survival in Latin American patients with diffuse large B-cell lymphoma: A multicenter cohort study of grupo de estudio latinoamericano de linfoproliferativos (GELL)

Rafael Pichardo-Rodriguez, Myrna Candelaria, Brady Beltran et al. Nov 03, 2025 pp. 5447-5447 10.1182/blood-2025-5447

Abstract Introduction: Diffuse large B-cell lymphoma (DLBCL) is the most common non-Hodgkin lymphoma globally. In Latin America (LATAM), lim...

Racial disparities in inpatient outcomes and resource utilization in multiple myeloma: An NIS-based analysis (2016–2022)

Ameerdad Khan, Naina Kumaari, Francis Gacek Nov 03, 2025 pp. 4407-4407 10.1182/blood-2025-4407

Abstract Background: Multiple myeloma (MM) disproportionately affects racial and ethnic minority populations, with growing evidence indicati...

National trends and disparities in primary (essential) hypertension and pulmonary embolism-related mortality in the United States from 1999-2023: A CDC wonder database analysis abstract

Hakim Wazir, Abdul Majid, Khushbakht Shah et al. Nov 03, 2025 pp. 8006-8006 10.1182/blood-2025-8006

Abstract Background: Chronic elevation of blood pressure, also known as Primary (essential) hypertension, is one of the...

ZBTB7A modulates response to BCL-2 inhibition by venetoclax in acute myeloid leukemia (AML)

Fu Jun Li, Xinyue Zhou, Pengcheng Zhang et al. Nov 03, 2025 pp. 3274-3274 10.1182/blood-2025-3274

Abstract Venetoclax, a selective BCL-2 inhibitor, in combination with azacytidine has become a standard-of-care treatment for older, and/or...

Preliminary experience from the ODYSSEY trial: Efficacy and safety of momelotinib in combination with luspatercept in patients with transfusion-dependent myelofibrosis

Prithviraj Bose, Jean-Christophe Ianotto, Regina Garcia-Delgado et al. Nov 03, 2025 pp. 3803-3803 10.1182/blood-2025-3803

Abstract Introduction: The management of patients with transfusion-dependent (TD) anemia represents an area of high medical need in myelofibr...

FLT3/ITD-driven noncanonical STAT1 S727 phosphorylation upregulates CD276, mediating CD8positive- T cell exhaustion and immune evasion in AML

Yun Wang, Shuzhao Chen, Shutong Liu et al. Nov 03, 2025 pp. 771-771 10.1182/blood-2025-771

Abstract FMS-like tyrosine kinase 3 internal tandem duplications (FLT3/ITD) mutation promotes leukemogenesis and confers poor prognosis in a...

Management and outcomes of acute coronary syndromes in patients with immune thrombocytopenia: A single-center real-world study

Jin Wu, Liqin Cao, Qiu-Sha Huang et al. Nov 03, 2025 pp. 4822-4822 10.1182/blood-2025-4822

Abstract Introduction Immune thrombocytopenia (ITP) is an autoimmune disorder causing low platelet counts and bleeding tendencies; however,...

Single center evaluation of TCRαβ+ T cell depletion using CliniMACS® plus platform: Optimizing cell selection for hematopoietic stem cell transplantation

Rilan Ou, Huan Li, Zhirui Ma et al. Nov 03, 2025 pp. 4215-4215 10.1182/blood-2025-4215

Abstract Introduction TCRαβ+ T cell-depletion is a promising ex vivo graft engineering technique that effectively reduces the risk of graft-...

Precision targeting of immune-mediated thrombotic thrombocytopenic purpura (iTTP) with chimeric auto-antigen receptor (CAAR) T cells

Roman Khadka, Ivan Cohen, Kalpana Parvathaneni et al. Nov 03, 2025 pp. 2341-2341 10.1182/blood-2025-2341

Abstract Introduction: Immune Thrombotic Thrombocytopenic Purpura (iTTP) is a life-threatening thrombotic microangiopathy characterized by t...

Age and race drive adult T-cell leukemia/lymphoma incidence in the United States, not income or urbanicity: 2000-2022 SEER analysis of 699 cases

Xiaoyi Zhang, Abhishek Kumar, Cho-Hao Lee et al. Nov 03, 2025 pp. 7160-7160 10.1182/blood-2025-7160

Abstract Background Adult T-cell leukemia/lymphoma (ATLL) is rare in the United States but clusters in specific racial a...

High cMPL expression identifies adult human long-term hematopoietic stem cells with superior multilineage and clonally balanced reconstitution potential

Daisuke Araki, Andre Larochelle Nov 03, 2025 pp. 853-853 10.1182/blood-2025-853

Abstract Thrombopoietin (TPO) and its receptor cMPL are key regulators of long-term hematopoietic stem cell (LT-HSC) maintenance. Clinical r...

Updated results from the Phase 1b/2 study of MK-1045, a novel CD19xCD3 T-cell engager, in adult participants with relapsed or refractory B-cell acute lymphoblastic leukemia

Ying Wang, Qingsong Yin, Jinhai Ren et al. Nov 03, 2025 pp. 647-647 10.1182/blood-2025-647

Abstract Introduction: MK-1045 (CN201) is a humanized bispecific IgG4 CD19xCD3 T-cell engager that has shown encouraging safety, tolerabilit...

Final efficacy results of the real-life ambispective urban study on frontline obinutuzumab-based immunochemotherapy for advanced follicular lymphoma

Antonio Pinto, Marco Caltagirone, Daniela Facchinello et al. Nov 03, 2025 pp. 5366-5366 10.1182/blood-2025-5366

Abstract Background: The GALLIUM trial established obinutuzumab-based immunochemotherapy as a new standard of care in first-line treatment f...

Association between monoclonal gammopathy of undetermined significance and cardiovascular disease risk among individuals with type 2 diabetes: A Taiwan nationwide Study

Tzeyu Michaud, Mei Wang, Pin-Xiang Chen et al. Nov 03, 2025 pp. 3966-3966 10.1182/blood-2025-3966

Abstract Introduction: Monoclonal gammopathy of undetermined significance (MGUS) is associated with increased risk of cardiovascular disease...

All Issues

Journal Info

Publisher Elsevier BV
ISSN 0006-4971
E-ISSN 1528-0020
Subject Health Sciences
Language English
View Full Journal Page